Glaukos Corporation
Trial Pipeline
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
NCT07400952
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
NCT07400926
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
NCT07400965
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
NCT07075718
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
NCT06848946
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
NCT06066645
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
NCT06057051
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
NCT05966493
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
NCT05314738
iStent Inject New Enrollment Post-Approval Study
NCT04624698
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
NCT05119920
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
NCT03519386
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01344187
Corneal Collagen Cross-Linking for Ectasia (CXL)
NCT00674661
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 32 |
| Phase 2 | 5 |
| Phase 3 | 4 |
| Phase 4 | 1 |
What the Pipeline for Glaukos Corporation Shows
According to the ClinicalTrials.gov registry, Glaukos Corporation is linked to 45 US clinical trials across every stage of research activity. Of those, 40 studies are currently recruiting — about 89% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 9% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Glaukos Corporation reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 37 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Glaukos Corporation is Glaucoma, Open-Angle with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.